enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2] This makes bladder cancer the sixth most common cancer in men, and the seventeenth in women. [69] When women are diagnosed with bladder cancer, they tend to have more advanced disease and consequently a poorer prognosis. [69]

4. Monomethyl auristatin E - Wikipedia

   en.wikipedia.org/wiki/Monomethyl_auristatin_E

   Glembatumumab (CR011, CDX-011), investigated for the treatment of breast cancer and melanoma [6] [7] targeting CD37: AGS67E, to treat lymphoid malignancy [8] [9] targeting tissue factor in recurrent or persistent cervical cancers that progress on or after first line chemotherapy regimens: tisotumab vedotin [10] Examples: Sofituzumab vedotin

5. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   cancer Axatilimab [27] Niktimvo: mab: humanized: CSF1R: Y: chronic graft-versus-host disease: Azintuxizumab vedotin [28] mab: chimeric/ humanized: CD319: cancer Bamlanivimab [29] mab: human: spike protein receptor binding domain (RBD) of SARS-CoV-2: US emergency use authorization (EUA) when used with etesevimab [30] COVID-19: Bapineuzumab [31 ...

8. Depatuxizumab mafodotin - Wikipedia

   en.wikipedia.org/wiki/Depatuxizumab_mafodotin

   Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. [1] [2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. [3] [4] This drug was developed by AbbVie. In May ...

9. Erdafitinib - Wikipedia

   en.wikipedia.org/wiki/Erdafitinib

   Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation , proliferation, angiogenesis , and ...